Hong Kong Biotech Uses AI to Cut Drug Development to 18 Months

Getting a new drug to patients typically takes years of painstaking research and testing. METiS TechBio just changed that timeline to 18 months using artificial intelligence.

The Hong Kong biotech company went public on Wednesday, and investors couldn't get enough. Shares jumped 173% on the first day of trading, opening at HK$28.68 compared to the offering price of HK$10.50.

So what's causing all the excitement? METiS TechBio uses AI algorithms to design what CEO Lai Tsai-Ta calls "nano-rockets." These tiny delivery vehicles can carry drugs directly where they're needed in the body, making treatments more effective and reducing side effects.

Lai, who earned his PhD from MIT, compares his company to SpaceX. "We use AI algorithms to design a large number of nano-rockets," he explained. "Pharma companies can load their own drugs onto our rockets through nanodelivery platforms to make products."

The company raised HK$2.11 billion (US$269.5 million) from its initial public offering. That makes it the third AI-driven drug developer to list in Hong Kong, following XtalPi in 2024 and Insilico Medicine in 2025.

The technology addresses one of medicine's biggest challenges: getting treatments to work better and faster. Traditional drug development is expensive and slow, often taking a decade or more from laboratory to pharmacy. By compressing that timeline to 18 months, METiS TechBio could help bring life-saving treatments to patients years earlier.

The Ripple Effect

The company's successful debut reflects growing confidence in AI's ability to solve complex medical problems. Both mainland Chinese and international investors snapped up shares, signaling strong belief in the technology's potential.

Mike Leung Kit-man, director at Wocom Securities, noted the trend. "Several AI-related IPOs have seen their share prices multiply since listing," he said. The enthusiasm suggests investors see real promise in using artificial intelligence to accelerate medical breakthroughs.

Hong Kong is becoming a hub for AI-driven drug development companies. The city's stock exchange has attracted multiple biotech firms that combine cutting-edge technology with pharmaceutical innovation, creating new possibilities for treating diseases that currently have limited options.

For patients waiting for new treatments, the 18-month development timeline could mean the difference between hope and despair.